OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PNTG$33.9260

Pennant Group Inc

Healthcare Facilities & ServicesVerified

Pennant Group Inc has a market capitalization of $1.19 billion and a price-to-earnings ratio of 40.08, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 3.56, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 26.20, which is a measure of the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization. The company's liquidity position is characterized as medium, with a current ratio of 1.14, indicating that it has slightly more current assets than current liabilities. In terms of profitability, Pennant Group Inc has a return on equity of 8.89% and a return on assets of 3.06%, which are metrics used to assess the company's efficiency in generating profits from its equity and assets, respectively. The company's operating margin is 5.48%, calculated as operating income divided by revenue, and its net profit margin is 3.12%, calculated as net income divided by revenue. These margins are below the industry median for healthcare facilities and services, indicating that the company may be less efficient in converting revenue into profit compared to its peers. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The company's capital structure includes long-term debt of $173.84 million, which represents a debt-to-equity ratio of 0.52, suggesting a moderate level of leverage. Looking at the company's growth trajectory, the current fiscal year is expected to show a revenue increase, with a projected growth rate that is in line with the industry average. The company's free cash flow is $20.30 million, which is a positive indicator of its ability to generate cash after accounting for capital expenditures. However, the company's net cash position is negative after subtracting total debt, which may indicate a potential liquidity risk. The risk assessment for Pennant Group Inc indicates a medium level of liquidity risk and a low level of dilution risk. The company's liquidity position is supported by its operating cash flow of $48.29 million, but the presence of long-term debt may affect its ability to meet short-term obligations. The company's dilution risk is low, as there is no significant dilution potential from basic shares outstanding. The company's risk profile is further supported by a current ratio of 1.14, which suggests that it has sufficient current assets to cover its current liabilities. Recent events and filings indicate that the company has a positive outlook from analysts, with a mean price target of $40.83 and a median price target of $40.50. The company has received strong-buy recommendations from four analysts and buy recommendations from three analysts, with no hold recommendations. This positive analyst sentiment may influence investor perceptions and the company's stock price. The company's recent financial performance and strategic initiatives are likely to be key factors in maintaining this positive outlook.

30-day price · PNTG+2.60 (+8.3%)
Low$28.19High$37.54Close$33.92As of22 May, 00:00 UTC
Profile
CompanyPennant Group Inc
TickerPNTG.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Pennant Group Inc operates in the healthcare sector, providing pharmaceutical services and equipment, and generates revenue primarily through the sale of pharmaceutical products and related services.

Classification. Pennant Group Inc is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

Pennant Group Inc has a market capitalization of $1.19 billion and a price-to-earnings ratio of 40.08, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 3.56, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 26.20, which is a measure of the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization. The company's liquidity position is characterized as medium, with a current ratio of 1.14, indicating that it has slightly more current assets than current liabilities. In terms of profitability, Pennant Group Inc has a return on equity of 8.89% and a return on assets of 3.06%, which are metrics used to assess the company's efficiency in generating profits from its equity and assets, respectively. The company's operating margin is 5.48%, calculated as operating income divided by revenue, and its net profit margin is 3.12%, calculated as net income divided by revenue. These margins are below the industry median for healthcare facilities and services, indicating that the company may be less efficient in converting revenue into profit compared to its peers. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The company's capital structure includes long-term debt of $173.84 million, which represents a debt-to-equity ratio of 0.52, suggesting a moderate level of leverage. Looking at the company's growth trajectory, the current fiscal year is expected to show a revenue increase, with a projected growth rate that is in line with the industry average. The company's free cash flow is $20.30 million, which is a positive indicator of its ability to generate cash after accounting for capital expenditures. However, the company's net cash position is negative after subtracting total debt, which may indicate a potential liquidity risk. The risk assessment for Pennant Group Inc indicates a medium level of liquidity risk and a low level of dilution risk. The company's liquidity position is supported by its operating cash flow of $48.29 million, but the presence of long-term debt may affect its ability to meet short-term obligations. The company's dilution risk is low, as there is no significant dilution potential from basic shares outstanding. The company's risk profile is further supported by a current ratio of 1.14, which suggests that it has sufficient current assets to cover its current liabilities. Recent events and filings indicate that the company has a positive outlook from analysts, with a mean price target of $40.83 and a median price target of $40.50. The company has received strong-buy recommendations from four analysts and buy recommendations from three analysts, with no hold recommendations. This positive analyst sentiment may influence investor perceptions and the company's stock price. The company's recent financial performance and strategic initiatives are likely to be key factors in maintaining this positive outlook.
Key takeaways
  • Pennant Group Inc has a high price-to-earnings ratio of 40.08, indicating a premium valuation relative to its earnings.
  • The company's return on equity of 8.89% is a positive indicator of its profitability and efficiency in using equity to generate returns.
  • The company's liquidity position is characterized as medium, with a current ratio of 1.14, suggesting a balanced approach to managing current assets and liabilities.
  • Analysts have a positive outlook on the company, with a mean price target of $40.83 and a median price target of $40.50.
  • The company's revenue is concentrated in a single segment, which may increase its exposure to market risks.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's operating margin of 5.48% and net profit margin of 3.12% are expected to remain stable, driven by consistent revenue and cost management.
  • **rd_outlook_rationale**: The company's research and development outlook is neutral, with no significant changes in R&D spending expected in the near term.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$947.7M
Gross profit$187.2M
Operating income$51.9M
Net income$29.6M
R&D
SG&A
D&A
SBC
Operating cash flow$48.3M
CapEx-$22.0M
Free cash flow$20.3M
Total assets$968.2M
Total liabilities$635.6M
Total equity$332.6M
Cash & equivalents
Long-term debt$173.8M
Valuation
Market price$33.92
Market cap$1.19B
Enterprise value$1.36B
P/E40.1
Reported non-GAAP P/E
EV/Revenue1.4
EV/Op income26.2
EV/OCF28.1
P/B3.6
P/Tangible book3.6
Tangible book$332.6M
Net cash-$173.8M
Current ratio1.1
Debt/Equity0.5
ROA3.1%
ROE8.9%
Cash conversion1.6%
CapEx/Revenue-2.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricPNTGActivity
Op margin5.5%7.7% medp25 -2.4% · p75 15.5%below median
Net margin3.1%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin19.8%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-2.3%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity52.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target40.83 USD
Median price target40.50 USD
High price target42.00 USD
Low price target40.00 USD
Mean recommendation1.43 (1=strong buy, 5=strong sell)
Strong-buy count4.00
Buy count3.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.35 USD
Last actual EPS1.18 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 01:13 UTC#3436249d
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 00:44 UTCJob: 2599752d